<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778345</url>
  </required_header>
  <id_info>
    <org_study_id>FUGES-021</org_study_id>
    <nct_id>NCT04778345</nct_id>
  </id_info>
  <brief_title>Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT in Peritoneal Carcinomatosis of Gastric Cancer</brief_title>
  <official_title>Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT to Detect Peritoneal Carcinomatosis in High-Risk Patients With Gastric Cancer: A Prospective, Single-Center, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the value of 68Ga-FAPI PET/CT in the diagnosis of gastric cancer&#xD;
      peritoneal carcinomatosis in high-risk patients compared with conventional abdominal enhanced&#xD;
      CT and 18F-FDG PET/CT. The patients with gastric adenocarcinoma (cT4/N+/M0-1) will be&#xD;
      studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will receive 68Ga-FAPI PET/CT on the 2nd day to 1st week of 18F-FDG PET/CT.&#xD;
      On PET/CT, omentum, peritoneum, and mesenteric lesions with increased radioactive uptake are&#xD;
      defined as suspicious peritoneal carcinomatosis. The number of these positive lesions, the&#xD;
      maximum standardized uptake value (SUVmax), median and range will be recorded. Subsequently,&#xD;
      the patients will undergo laparoscopic exploration, and if radical resection is assessed,&#xD;
      radical gastrectomy (D2 lymph node dissection) will be performed. If a radical resection is&#xD;
      not feasible, for patients with peritoneal carcinomatosis detected, one metastasis will be&#xD;
      taken for rapid frozen diagnosis. After the peritoneal carcinomatosis is confirmed, the&#xD;
      metastases seen under laparoscopy will be matched with the suspicious peritoneal&#xD;
      carcinomatosis on the three preoperative imaging examinations. The intraoperative findings&#xD;
      are used as the gold standard to compare the detection efficiency of the three imaging&#xD;
      examinations for peritoneal carcinomatosis. Patients with unresected tumors will receive 4&#xD;
      cycles of conversion therapy or neoadjuvant therapy. After the treatment, 18F-FDG PET/CT and&#xD;
      68Ga-FAPI PET/CT will be performed again. If necessary, patients will be subjected to a&#xD;
      second laparoscopic exploration, and radical gastrectomy (D2 lymph node dissection) will be&#xD;
      performed for appropriate patients. If a radical resection is still not feasible, for&#xD;
      patients with peritoneal carcinomatosis detected, biopsy of metastases will be performed if&#xD;
      necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic efficacy for peritoneal carcinomatosis</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of 68Ga-FAPI PET/CT for peritoneal carcinomatosis in comparison with 18F-FDG PET/CT and abdominal enhanced CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum standardized uptake value [SUVmax (for PET/CT only)] for peritoneal carcinomatosis</measure>
    <time_frame>One month after surgery</time_frame>
    <description>SUVmax of 68Ga-FAPI PET/CT for peritoneal carcinomatosis in comparison with 18F-FDG PET/CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive value for peritoneal carcinomatosis by using radiomic algorithm</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Prediction value of three kinds of imaging examination for peritoneal carcinomatosis by using radiomic algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic efficacy for primary lesions</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Sensitivity, specificity, accuracy, PPV and NPV of 68Ga-FAPI PET/CT for primary lesions in comparison with 18F-FDG PET/CT and abdominal enhanced CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUVmax (for PET/CT only) for primary lesions</measure>
    <time_frame>One month after surgery</time_frame>
    <description>SUVmax of 68Ga-FAPI PET/CT for primary lesions in comparison with 18F-FDG PET/CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic efficacy for metastatic lymph nodes</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Sensitivity, specificity, accuracy, PPV and NPV of 68Ga-FAPI PET/CT for metastatic lymph nodes in comparison with 18F-FDG PET/CT and abdominal enhanced CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUVmax (for PET/CT only) for metastatic lymph nodes</measure>
    <time_frame>One month after surgery</time_frame>
    <description>SUVmax of 68Ga-FAPI PET/CT for metastatic lymph nodes in comparison with 18F-FDG PET/CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the expression of fibroblast activation protein (FAP) and 68Ga-FAPI uptake in different pathological types of peritoneal carcinomatosis</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Analyzing the correlation between the SUVmax of 68Ga-FAPI in peritoneal carcinomatosis with different pathological types and FAP identified by pathological examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the expression of FAP and 68Ga-FAPI uptake in different pathological types of primary lesions</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Analyzing the correlation between the SUVmax of 68Ga-FAPI in primary lesions with different pathological types and FAP identified by pathological examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the expression of FAP and 68Ga-FAPI uptake in different pathological types of metastatic lymph nodes</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Analyzing the correlation between the SUVmax of 68Ga-FAPI in metastatic lymph nodes with different pathological types and FAP identified by pathological examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of conversion therapy efficacy</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Predictive value of three kinds of imaging examination for gastric cancer in conversion therapy response assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression-free survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>The relationship between three kinds of imaging examination and the patient's 1-year progression-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression patterns</measure>
    <time_frame>12 months</time_frame>
    <description>The relationship between the three types of imaging examinations and the patient's 1-year progression patterns</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Enhanced CT</condition>
  <condition>18F-FDG PET/CT</condition>
  <condition>68Ga-FAPI PET/CT</condition>
  <condition>Gastric Cancer</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>18F-FDG PET/CT and 68Ga-FAPI PET/CT scan after abdominal enhanced CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the patient received abdominal enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT were further performed. The interval between 18F-FDG PET/CT and 68Ga-FAPI PET/CT was 2 days to 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-FAPI PET/CT scan</intervention_name>
    <description>Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging after 18F-FDG PET/CT scan during 2 days and 1 week.</description>
    <arm_group_label>18F-FDG PET/CT and 68Ga-FAPI PET/CT scan after abdominal enhanced CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 75 years&#xD;
&#xD;
          2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or&#xD;
             poorly differentiated) confirmed pathologically by endoscopic biopsy&#xD;
&#xD;
          3. The clinical tumor stage before PET/CT scan was evaluated as cT4/N+/M0-1, according to&#xD;
             the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Eighth Edition&#xD;
&#xD;
          4. Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)&#xD;
&#xD;
          5. American Society of Anesthesiology score (ASA) class I, II, or III&#xD;
&#xD;
          6. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women during pregnancy or breast-feeding&#xD;
&#xD;
          2. Severe mental disorder&#xD;
&#xD;
          3. History of previous abdominal inflammatory diseases (such as peritonitis,&#xD;
             pancreatitis, cholecystitis, inflammatory bowel disease)&#xD;
&#xD;
          4. History of unstable angina or myocardial infarction within past six months&#xD;
&#xD;
          5. History of cerebrovascular accident within past six months&#xD;
&#xD;
          6. History of continuous systematic administration of corticosteroids within one month&#xD;
&#xD;
          7. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by&#xD;
             gastric cancer&#xD;
&#xD;
          8. Forced expiratory volume in 1 second (FEV1)&lt;50% of predicted values&#xD;
&#xD;
          9. History of allergy to tracer agents of PET/CT&#xD;
&#xD;
         10. History of allergy to contrast agents of CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Ming Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang-Ming Huang, MD</last_name>
    <phone>+86-13805069676</phone>
    <email>hcmlr2002@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zu-Kai Wang, MD</last_name>
    <phone>+86-15659036263</phone>
    <email>413966027@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastric Surgery</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020 Aug 29;396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5. Review.</citation>
    <PMID>32861308</PMID>
  </reference>
  <reference>
    <citation>Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000 Aug;26(4):243-55. Review.</citation>
    <PMID>10913380</PMID>
  </reference>
  <reference>
    <citation>Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol. 2013 Mar;68(3):251-5. doi: 10.1016/j.crad.2012.07.015. Epub 2012 Sep 14.</citation>
    <PMID>22985749</PMID>
  </reference>
  <reference>
    <citation>Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer. 2007;10(1):29-34. Epub 2007 Feb 23.</citation>
    <PMID>17334715</PMID>
  </reference>
  <reference>
    <citation>Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK Jr, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H; National Comprehensive Cancer Network. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 1;11(5):531-46.</citation>
    <PMID>23667204</PMID>
  </reference>
  <reference>
    <citation>Smyth E, Schöder H, Strong VE, Capanu M, Kelsen DP, Coit DG, Shah MA. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. 2012 Nov 15;118(22):5481-8. doi: 10.1002/cncr.27550. Epub 2012 May 1.</citation>
    <PMID>22549558</PMID>
  </reference>
  <reference>
    <citation>Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9.</citation>
    <PMID>2402505</PMID>
  </reference>
  <reference>
    <citation>Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014 Jun;8(5-6):454-63. doi: 10.1002/prca.201300095. Epub 2014 Mar 24. Review.</citation>
    <PMID>24470260</PMID>
  </reference>
  <reference>
    <citation>Rettig WJ, Su SL, Fortunato SR, Scanlan MJ, Raj BK, Garin-Chesa P, Healey JH, Old LJ. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer. 1994 Aug 1;58(3):385-92.</citation>
    <PMID>7519584</PMID>
  </reference>
  <reference>
    <citation>Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. (68)Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.</citation>
    <PMID>30954939</PMID>
  </reference>
  <reference>
    <citation>Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832. doi: 10.1007/s00259-020-04769-z. Epub 2020 Mar 28.</citation>
    <PMID>32222810</PMID>
  </reference>
  <reference>
    <citation>Pang Y, Zhao L, Luo Z, Hao B, Wu H, Lin Q, Sun L, Chen H. Comparison of (68)Ga-FAPI and (18)F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology. 2021 Feb;298(2):393-402. doi: 10.1148/radiol.2020203275. Epub 2020 Dec 1.</citation>
    <PMID>33258746</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Jang YJ, Park SS, Park SH, Kim SJ, Mok YJ, Kim CS. Surgical outcomes and prognostic factors for T4 gastric cancers. Asian J Surg. 2009 Oct;32(4):198-204. doi: 10.1016/S1015-9584(09)60395-X.</citation>
    <PMID>19892622</PMID>
  </reference>
  <reference>
    <citation>Kurita N, Shimada M, Utsunomiya T, Iwata T, Nishioka M, Yoshikawa K, Miyatani T, Higashijima J, Nakao T. Predictive factors of peritoneal metastasis in gastric cancer. Hepatogastroenterology. 2010 Jul-Aug;57(101):980-3.</citation>
    <PMID>21033263</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

